Design, Synthesis and Biological Evaluation of Novel Pyrazole-based Compounds As Potential Chemotherapeutic Agents

Overview

Journal Future Med Chem

Specialties Chemistry
Pharmacy

Date 2024 Aug 7

PMID 39109431

Authors

Maiy Y Jaballah

Nooran S Elleboudy

Marwa Sharaky

Khaled A M Abouzid

Mai I Shahin

Affiliations

Soon will be listed here.

Abstract

Design and synthesis of pyrazole-based chemotherapeutic agents. A series of novel diphenyl pyrazole-chalcone derivatives were synthesized and assessed for their cytotoxic activities against 14 cancer cell lines and their antimicrobial activities against MRSA and along with their safety using HSF normal cell line. Majority of the compounds showed moderate-to-significant anticancer activity with selective high percentage inhibition (>80%) against HNO-97 while being nontoxic toward normal cells. Compounds and were the most potent congeners with IC of 10 and 10.56 μM respectively. The synthesized compounds exhibited moderate to potent antimicrobial activities. Interestingly, compound exhibited a minimum inhibitory concentration of 15.7 μg/ml against MRSA; and a minimum inhibitory concentration of 7.8 μg/ml versus .

References

Viegas-Junior C, Danuello A, da Silva Bolzani V, Barreiro E, Fraga C . Molecular hybridization: a useful tool in the design of new drug prototypes. Curr Med Chem. 2007; 14(17):1829-52. DOI: 10.2174/092986707781058805. View

Siddiqui Z, Mohammed Musthafa T, Ahmad A, Khan A . Thermal solvent-free synthesis of novel pyrazolyl chalcones and pyrazolines as potential antimicrobial agents. Bioorg Med Chem Lett. 2011; 21(10):2860-5. DOI: 10.1016/j.bmcl.2011.03.080. View

Nepali K, Lee H, Liou J . Nitro-Group-Containing Drugs. J Med Chem. 2018; 62(6):2851-2893. DOI: 10.1021/acs.jmedchem.8b00147. View

Vitaku E, Smith D, Njardarson J . Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals. J Med Chem. 2014; 57(24):10257-74. DOI: 10.1021/jm501100b. View

Tawari N, Bairwa R, Ray M, Rajan M, Degani M . Design, synthesis, and biological evaluation of 4-(5-nitrofuran-2-yl)prop-2-en-1-one derivatives as potent antitubercular agents. Bioorg Med Chem Lett. 2010; 20(21):6175-8. DOI: 10.1016/j.bmcl.2010.08.127. View

Rajendran G, Bhanu D, Aruchamy B, Ramani P, Pandurangan N, Bobba K . Chalcone: A Promising Bioactive Scaffold in Medicinal Chemistry. Pharmaceuticals (Basel). 2022; 15(10). PMC: 9607481. DOI: 10.3390/ph15101250. View

Verma R, Verma S, Rakesh K, Girish Y, Ashrafizadeh M, Sharath Kumar K . Pyrazole-based analogs as potential antibacterial agents against methicillin-resistance staphylococcus aureus (MRSA) and its SAR elucidation. Eur J Med Chem. 2021; 212:113134. DOI: 10.1016/j.ejmech.2020.113134. View

Frieri M, Kumar K, Boutin A . Antibiotic resistance. J Infect Public Health. 2016; 10(4):369-378. DOI: 10.1016/j.jiph.2016.08.007. View

Miethke M, Pieroni M, Weber T, Bronstrup M, Hammann P, Halby L . Towards the sustainable discovery and development of new antibiotics. Nat Rev Chem. 2021; 5(10):726-749. PMC: 8374425. DOI: 10.1038/s41570-021-00313-1. View

10.

Petersen P . Strengthening the prevention of oral cancer: the WHO perspective. Community Dent Oral Epidemiol. 2005; 33(6):397-9. DOI: 10.1111/j.1600-0528.2005.00251.x. View

11.

Rodrigues M, Silva S, Azeredo J, Henriques M . Novel strategies to fight Candida species infection. Crit Rev Microbiol. 2014; 42(4):594-606. DOI: 10.3109/1040841X.2014.974500. View

12.

Karrouchi K, Radi S, Ramli Y, Taoufik J, Mabkhot Y, Al-Aizari F . Synthesis and Pharmacological Activities of Pyrazole Derivatives: A Review. Molecules. 2018; 23(1). PMC: 6017056. DOI: 10.3390/molecules23010134. View

13.

Balouiri M, Sadiki M, Ibnsouda S . Methods for evaluating antimicrobial activity: A review. J Pharm Anal. 2018; 6(2):71-79. PMC: 5762448. DOI: 10.1016/j.jpha.2015.11.005. View

14.

Dan W, Dai J . Recent developments of chalcones as potential antibacterial agents in medicinal chemistry. Eur J Med Chem. 2019; 187:111980. DOI: 10.1016/j.ejmech.2019.111980. View

15.

Shelke S, Mhaske G, Bonifacio V, Gawande M . Green synthesis and anti-infective activities of fluorinated pyrazoline derivatives. Bioorg Med Chem Lett. 2012; 22(17):5727-30. DOI: 10.1016/j.bmcl.2012.06.072. View

16.

Bebernitz G, Argentieri G, Battle B, Brennan C, Balkan B, Burkey B . The effect of 1,3-diaryl-[1H]-pyrazole-4-acetamides on glucose utilization in ob/ob mice. J Med Chem. 2001; 44(16):2601-11. DOI: 10.1021/jm010032c. View

17.

Shoemaker R . The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006; 6(10):813-23. DOI: 10.1038/nrc1951. View

18.

Ugalde-Arbizu M, Aguilera-Correa J, Garcia-Almodovar V, Ovejero-Paredes K, Diaz-Garcia D, Esteban J . Dual Anticancer and Antibacterial Properties of Silica-Based Theranostic Nanomaterials Functionalized with Coumarin343, Folic Acid and a Cytotoxic Organotin(IV) Metallodrug. Pharmaceutics. 2023; 15(2). PMC: 9962538. DOI: 10.3390/pharmaceutics15020560. View

19.

Ahmed A, Mohamed M, Allam R, Nafady A, Mohamed S, Gouda A . Design, synthesis, and molecular docking of novel pyrazole-chalcone analogs of lonazolac as 5-LOX, iNOS and tubulin polymerization inhibitors with potential anticancer and anti-inflammatory activities. Bioorg Chem. 2022; 129:106171. DOI: 10.1016/j.bioorg.2022.106171. View

20.

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View